Elaine O Bigelow, Amanda L Blackford, Danielle F Eytan, David W Eisele, Carole Fakhry
BACKGROUND: The prevalence of survivors of oropharyngeal cancer (OPC) is increasing due to improved survival for individuals with human papillomavirus (HPV)-related disease. Although elderly survivors of OPC are known to have a high burden of comorbidities, to the authors' knowledge it is unknown how this compares with a similar cohort without a history of cancer. METHODS: The current retrospective, cross-sectional study included individuals with a first incident primary diagnosis of OPC from 2004 through 2011 from the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked databases and matched controls...
January 14, 2020: Cancer
Jared M Weiss, Nathan Pennell, Allison M Deal, Daniel Morgenzstern, Daniel S Bradford, Jeffrey Crane, Howard Jack West, Carrie Lee, Chad Pecot, James P Stevenson, William Irvin, Mark Socinski, Tom Stinchcombe, Liza C Villaruz, Hyman B Muss
BACKGROUND: The selection of later-line treatment for older patients with AJCC (version 7) stage IV non-small cell lung cancer (NSCLC) remains controversial. Nanoparticle albumin-bound (nab)-paclitaxel is approved with carboplatin for the first-line treatment of patients with NSCLC and subgroup analysis of phase 3 data has suggested superior survival in older patients. METHODS: The authors conducted a phase 2 study of nab-paclitaxel in 42 patients aged ≥70 years who had been treated previously with a platinum doublet regimen; patients also could have received a PD-1 inhibitor...
January 14, 2020: Cancer
Bora Youn, Nikolaos A Trikalinos, Vincent Mor, Ira B Wilson, Issa J Dahabreh
BACKGROUND: Limited data exist regarding the characteristics and survival outcomes of older adults with non-small cell lung cancer (NSCLC) who receive immune checkpoint inhibitors in routine oncology practice. METHODS: Using the Surveillance, Epidemiology, and End Results-Medicare linked database, we identified 1256 patients aged ≥65 years who were diagnosed with pathologically confirmed stage I to stage IV NSCLC between 2002 and 2015 and initiated nivolumab or pembrolizumab in 2016...
January 14, 2020: Cancer
Lindsay Clough, A Rana Bayakly, Kevin C Ward, Mohammad K Khan, Suephy C Chen, Mary Jo Lechowicz, Christopher R Flowers, Pamela B Allen, Jeffrey M Switchenko
BACKGROUND: Cutaneous T-cell lymphoma (CTCL) is a rare form of non-Hodgkin lymphoma arising in the skin. Geographic clustering of CTCL has recently been reported, but its association with environmental factors is unknown. Benzene and trichloroethylene (TCE) are environmental toxins with carcinogenic properties. The authors investigated associations between geographic clustering of CTCL incidence in the state of Georgia with benzene and TCE exposure. METHODS: The statewide county-level incidence of CTCL within Georgia was obtained from the Georgia Cancer Registry for the years 1999 to 2015...
January 14, 2020: Cancer
Gordon Taylor Moffat, Andrew S Epstein, Eileen M O'Reilly
No abstract text is available yet for this article.
January 14, 2020: Cancer
Charu Aggarwal, Corey J Langer
No abstract text is available yet for this article.
January 14, 2020: Cancer
Riccardo Caccialanza, Federica Lobascio, Silvia Brugnatelli, Paolo Pedrazzoli
No abstract text is available yet for this article.
January 14, 2020: Cancer
Zoe H Fullerton, Santino S Butler, Brandon A Mahal, Vinayak Muralidhar, Jonathan D Schoenfeld, Roy B Tishler, Danielle N Margalit
BACKGROUND: There is substantial variation in head and neck cancer (HNC) mortality and competing mortality among patients with HNC. In this study, the authors characterize the causes and risks of short-term mortality among patients with oropharynx cancer (OPC) and how these risks differ by human papillomavirus (HPV) status. METHODS: A custom Surveillance, Epidemiology, and End Results (SEER) data set with HPV status was used to identify 4930 patients with OPC who were diagnosed with nonmetastatic (M0) disease from 2013 to 2014, including 3560 (72...
January 13, 2020: Cancer
Carmen L Wilson, Tara M Brinkman, Cathleen Cook, Sujuan Huang, Geehong Hyun, Daniel M Green, Wayne L Furman, Nickhill Bhakta, Matthew J Ehrhardt, Matthew J Krasin, Leslie L Robison, Kirsten K Ness, Melissa M Hudson
BACKGROUND: The objective of this study was to characterize chronic disease, health-related quality of life (HRQOL), emotional distress, and social attainment among long-term survivors of neuroblastoma. METHODS: Chronic health conditions among 136 ≥10-year neuroblastoma survivors (median age, 31.9 years; range, 20.2-54.6 years) and 272 community controls (median age, 34.7 years; range, 18.3-59.6 years) were graded with a modified version of the Common Terminology Criteria for Adverse Events (version 4...
January 10, 2020: Cancer
Aaron R Hansen, Kari Ala-Leppilampi, Chris McKillop, Lillian L Siu, Philippe L Bedard, Albiruni R Abdul Razak, Anna Spreafico, Srikala S Sridhar, Natasha Leighl, Marcus O Butler, David Hogg, Adrian Sacher, Amit M Oza, Rany Al-Agha, Catherine Maurice, Christopher T Chan, Shane Shapera, Jordan J Feld, Rosane Nisenbaum, Kimberly Webster, David Cella, Janet Parsons
BACKGROUND: Patients with cancer who are treated with immune checkpoint modulators (ICMs) have their health-related quality of life (HRQOL) measured using general patient-reported outcome (PRO) tools. To the authors' knowledge, no instrument has been developed to date specifically for patients treated with ICMs. The objective of the current study was to develop a toxicity subscale PRO instrument for patients treated with ICMs to assess HRQOL. METHODS: Input was collected from a systematic review as well as patients and physicians experienced with ICM treatment...
January 8, 2020: Cancer
Cameron M Phillips, Ambica Parmar, Helen Guo, Deborah Schwartz, Wanrudee Isaranuwatchai, Jaclyn Beca, Wei Dai, Jessica Arias, Scott Gavura, Kelvin K W Chan
BACKGROUND: Although increasing evidence has suggested that an efficacy-effectiveness gap exists between clinical trial (CT) and real-world evidence (RWE), to the authors' knowledge, the magnitude of this difference remains undercharacterized. The objective of the current study was to quantify the magnitude of survival and toxicity differences between CT and RWE for contemporary cancer systemic therapies. METHODS: Patients receiving cancer therapies funded under Cancer Care Ontario's New Drug Funding Program (NDFP) were identified...
January 8, 2020: Cancer
Christopher J Recklitis, Jaime E Blackmon, Grace Chang
BACKGROUND: The current study was conducted to evaluate the Patient-Reported Outcomes Measurement Information System Depression Short Form (PROMIS-D-SF) as a screening measure for young adult cancer survivors (YACS) compared with a structured diagnostic interview. METHODS: A total of 249 YACS (aged 18-40 years) completed the PROMIS-D-SF and Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (SCID). Based on the SCID, participants were classified as having: 1) an SCID depression diagnosis; 2) depression symptoms without an SCID diagnosis; or 3) no depression symptoms...
January 8, 2020: Cancer
Ingrid Tonning Olsson, Tara M Brinkman, Mingjuan Wang, Matthew J Ehrhardt, Pia Banerjee, Daniel A Mulrooney, I-Chan Huang, Kirsten K Ness, Michael W Bishop, Deokumar Srivastava, Leslie L Robison, Melissa M Hudson, Kevin R Krull
BACKGROUND: To the authors' knowledge, few studies to date have examined long-term neurocognitive outcomes in survivors of childhood soft-tissue sarcoma. METHODS: A total of 150 survivors (41% of whom were female with a mean current age of 33 years [SD, 8.9 years] and a time since diagnosis of 24 years [SD, 8.7 years]) and 349 community controls (56% of whom were female with a mean current age of 35 years [SD, 10.2 years]) completed comprehensive neuropsychological testing, echocardiography, electrocardiography, pulmonary function tests, endocrine evaluation, and physical examination...
January 8, 2020: Cancer
Dawn L Hershman, Melissa K Accordino, Sherry Shen, Donna Buono, Katherine D Crew, Kevin Kalinsky, Meghna S Trivedi, Chin Hur, Jianhua Hu, Joseph M Unger, Jason D Wright
BACKGROUND: Cardiovascular disease (CVD) is the leading cause of death among patients with early-stage breast cancer (BC), but adherence to cardiovascular disease risk factor (CVD-RF) medications is reported to be poor in BC survivors. The objective of the current study was to determine the association between nonadherence to CVD-RF medications and cardiovascular events in BC survivors. METHODS: The authors included patients with stages I to III BC from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database who had Medicare part D coverage and who were taking at least 1 CVD-RF medication prior to their BC diagnosis (2008-2013)...
January 8, 2020: Cancer
Emi Takeuchi, Youngmee Kim, Kelly M Shaffer, Rachel S Cannady, Charles S Carver
BACKGROUND: Fear of cancer recurrence (FCR) has been associated with cancer screening behaviors among cancer survivors, but to the authors' knowledge, the question of whether the same is true for caregivers is unknown. The current study investigated the extent to which FCR among caregivers predicted their cancer screening behaviors years after their relatives' cancer diagnosis. METHODS: A total of 813 caregivers (67% of whom were female, mean age of 56 years, and 92% non-Hispanic white) completed surveys 2 years (T1) and 8 years (T2) after their patients' cancer diagnosis...
January 8, 2020: Cancer
Rajshekhar Chakraborty, Irbaz Bin Riaz, Saad Ullah Malik, Naimisha Marneni, Alex Mejia Garcia, Faiz Anwer, Alok A Khorana, S Vincent Rajkumar, Shaji Kumar, M Hassan Murad, Zhen Wang, Safi U Khan, Navneet S Majhail
BACKGROUND: Thromboprophylaxis is routinely used with lenalidomide-based regimens in multiple myeloma because of a substantial risk of venous thromboembolism (VTE). However, little is known about the incidence of VTE with contemporary lenalidomide-based regimens. The objective of the current study was to estimate the incidence of VTE despite thromboprophylaxis with currently used lenalidomide-based regimens in patients with myeloma. METHODS: The Ovid MEDLINE, Embase, and Cochrane databases were queried from study inception to January 2019 for keywords to cover the following concepts: "lenalidomide," "venous thromboembolism," and "multiple myeloma...
January 8, 2020: Cancer
Nadine J Barrett, Elisa M Rodriguez, Ronaldo Iachan, Terry Hyslop, Kearston L Ingraham, Gem M Le, Kelly Martin, Rodney C Haring, Natalie A Rivadeneira, Deborah O Erwin, Laura J Fish, Deirdre Middleton, Robert A Hiatt, Steven R Patierno, Urmimala Sarkar, Elizabeth A Gage-Bouchard
BACKGROUND: Engaging diverse populations in biomedical research, including biospecimen donation, remains a national challenge. This study examined factors associated with an invitation to participate in biomedical research, intent to participate in biomedical research in the future, and participation in biomedical research and biospecimen donation among a diverse, multilingual, community-based sample across 3 distinct geographic areas. METHODS: Three National Cancer Institute-designated cancer centers engaged in community partnerships to develop and implement population health assessments, reaching a convenience sample of 4343 participants spanning their respective catchment areas...
January 7, 2020: Cancer
Erin L Symonds, Susanne K Pedersen, David Murray, Susan E Byrne, Amitesh Roy, Christos Karapetis, Paul Hollington, Philippa Rabbitt, Frederick S Jones, Lawrence LaPointe, Eva Segelov, Graeme P Young
BACKGROUND: The sensitive detection of recurrent colorectal cancer (CRC) by the measurement of circulating tumor DNA (ctDNA) might improve the chance of a cure. This study compared a quantitative methylated ctDNA test with carcinoembryonic antigen (CEA) in the setting of surveillance for recurrence. METHODS: Blood samples collected either during surveillance or within 12 months of the confirmation of recurrence were assayed for ctDNA (methylated branched-chain amino acid transaminase 1 [BCAT1]/Ikaros family zinc-finger 1 protein [IKZF1]) and CEA...
January 7, 2020: Cancer
Cathy D Meade, Clement K Gwede
No abstract text is available yet for this article.
January 7, 2020: Cancer
Brandon A Mahal, Mohammed Alshalalfa, Shuang G Zhao, Himisha Beltran, William S Chen, Fallon Chipidza, Elai Davicioni, R Jeffrey Karnes, Sheng-Yu Ku, Tamara L Lotan, Vinayak Muralidhar, Timothy R Rebbeck, Edward M Schaeffer, Daniel E Spratt, Felix Y Feng, Paul L Nguyen
BACKGROUND: The progression of prostate cancer is a complex, multistep process that involves molecular alterations in cells of the tumor and the microenvironment, with associated interactions between the stroma and epithelium. Genomic expression analyses of stromal infiltration markers were performed to determine the significance thereof in prostate cancer. METHODS: Genome-wide expression profiles of formalin-fixed, paraffin-embedded radical prostatectomy samples were evaluated from a prospective registry cohort (n = 5239) and 3 retrospective institutional cohorts (n = 1135)...
January 6, 2020: Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"